NTLA Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -1489.54% compared to Intellia Therapeutics's net margin of --. Intellia Therapeutics's return on equity of -51.64% beat Perspective Therapeutics's return on equity of --.

Intellia Therapeutics has a consensus price target of $57.76, signalling upside risk potential of 466.29%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 361.43%. Given that Intellia Therapeutics has higher upside potential than Perspective Therapeutics, analysts believe Intellia Therapeutics is more attractive than Perspective Therapeutics.

Intellia Therapeutics has a beta of 1.832, which suggesting that the stock is 83.195% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $9.1M, which are larger than Perspective Therapeutics quarterly revenues of --. Intellia Therapeutics's net income of -$135.7M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 22.72x versus 18.90x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -1489.54% compared to Intellia Therapeutics's net margin of 10.05%. Intellia Therapeutics's return on equity of -51.64% beat Electromed's return on equity of 15.62%.

Intellia Therapeutics has a consensus price target of $57.76, signalling upside risk potential of 466.29%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 10.85%. Given that Intellia Therapeutics has higher upside potential than Electromed, analysts believe Intellia Therapeutics is more attractive than Electromed.

Intellia Therapeutics has a beta of 1.832, which suggesting that the stock is 83.195% more volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $9.1M, which are smaller than Electromed quarterly revenues of $14.7M. Intellia Therapeutics's net income of -$135.7M is lower than Electromed's net income of $1.5M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Electromed's PE ratio is 41.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 22.72x versus 4.65x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -1489.54% compared to Intellia Therapeutics's net margin of 36.03%. Intellia Therapeutics's return on equity of -51.64% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Intellia Therapeutics has a consensus price target of $57.76, signalling upside risk potential of 466.29%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,042.95 which suggests that it could grow by 49.66%. Given that Intellia Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Intellia Therapeutics is more attractive than Regeneron Pharmaceuticals.

Intellia Therapeutics has a beta of 1.832, which suggesting that the stock is 83.195% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $9.1M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Intellia Therapeutics's net income of -$135.7M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 22.72x versus 5.79x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -1489.54% compared to Intellia Therapeutics's net margin of -17.98%. Intellia Therapeutics's return on equity of -51.64% beat Xtant Medical Holdings's return on equity of -35.98%.

Intellia Therapeutics has a consensus price target of $57.76, signalling upside risk potential of 466.29%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 351.1%. Given that Intellia Therapeutics has higher upside potential than Xtant Medical Holdings, analysts believe Intellia Therapeutics is more attractive than Xtant Medical Holdings.

Intellia Therapeutics has a beta of 1.832, which suggesting that the stock is 83.195% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $9.1M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Intellia Therapeutics's net income of -$135.7M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 22.72x versus 0.58x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.